10x Genomics (TXG) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.03
- Estimate
- -$0.02
- Surprise
- +258.4%
- Revenue (period 2026-06-30)
- $151.0M
- Score today
- 4.2/10
Revenue source: xbrl.
How the report landed
10x Genomics (TXG) beat the -$0.02 estimate with adjusted EPS of $0.03 — a large 258.4% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates TXG Hold at 4.2/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +258.4% surprise compares with a +205.3% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: single-supplier components
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $72.39
- Price target
- $100.75
- Stop
- $67.32
- Upside to target
- +39.2%
Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.
TXG at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $9.43B
- P/E (fwd)
- 944.2
- 52-week range
- $11.80–$102.81
- Off 52-week high
- 29.6%
- RSI (14)
- 37
- Volume vs avg
- 1.02×
- Score today
- 4.2/10